Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,403 across all filing types
Latest filing 2019-06-20 Investor Presentation
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
Innate Pharma to host key opinion leader call on IPH4102 “TELLOMAK” clinical trial design and rationale
Investor Presentation Classification · 1% confidence The document is a press release dated June 20, 2019, announcing that Innate Pharma will host a Key Opinion Leader (KOL) call to discuss the clinical trial design and rationale for their drug IPH4102 ('TELLOMAK'). It provides details about the speakers, the time/date of the event, dial-in numbers, and links for access. This content is characteristic of an announcement regarding an upcoming investor or scientific event, rather than a formal financial report (like 10-K or IR) or a transcript of a past event. Since it is an announcement about a scientific/clinical update event, it most closely aligns with an Investor Presentation (IP) or a general announcement. Given the focus on presenting clinical trial design and rationale to KOLs and investors, 'Investor Presentation' (IP) is a strong fit, as these calls often involve presentation materials. However, since the document itself is the *announcement* of the call, and not the presentation materials or the transcript, it functions as a general corporate update. In the context of the provided definitions, it is a specific corporate communication event announcement. It is not a formal financial report, earnings release, or a transcript. It is an announcement about a presentation/discussion. If the content were the actual presentation slides, IP would be correct. As it is the announcement of a call featuring a presentation, it fits best under the general category of investor communication, but none of the codes perfectly capture 'Event Announcement'. Given the options, and recognizing that these calls often accompany or precede investor materials, 'Investor Presentation' (IP) is the closest fit for the subject matter being discussed (clinical trial design/rationale), although 'Regulatory Filings' (RNS) could serve as a fallback for specific event announcements. Since the content is highly focused on clinical trial data presentation, IP is chosen over the generic RNS.
2019-06-20 English
Innate Pharma annonce son intention de procéder à une offre au public aux États-Unis
Capital/Financing Update Classification · 1% confidence The document is a press release announcing the company's intention to conduct a public offering of its ordinary shares in the form of American Depositary Shares (ADSs) in the United States and a concurrent private placement outside the US. It explicitly mentions submitting a draft registration statement (Form F-1) to the SEC and references Rule 135 of the Securities Act of 1933. This activity—raising capital through the issuance of new securities—falls directly under the definition of a financing activity. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is short (2821 chars) and it is an announcement, but the specific nature of the announcement (public offering/financing) overrides the general 'RPA' or 'RNS' fallback.
2019-06-12 French
Innate Pharma announces intention to conduct a registered offering in the United States
Capital/Financing Update Classification · 1% confidence The document is a press release announcing the company's intention to conduct a registered public offering of ordinary shares in the United States, involving the confidential submission of a draft registration statement on Form F-1 to the SEC. It also mentions a simultaneous private placement. This activity directly relates to fundraising, financing, and capital structure changes. Therefore, the most appropriate classification is 'Capital/Financing Update' (CAP). The document length (2537 chars) is short, but it is the primary announcement of the financing event itself, not just an announcement of a report, making CAP more specific than RPA or RNS.
2019-06-12 English
Présentation du design de l’essai « TELLOMAK» ainsi que des données précliniques d’IPH4102 dans le LTP à l’ICML 2019
Regulatory Filings Classification · 1% confidence The document is explicitly titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces updates regarding a clinical trial design ('TELLOMAK') and preclinical data for a drug (IPH4102) to be presented at a conference (ICML 2019). It also announces a conference call for experts. This structure—a brief announcement detailing upcoming data presentations or key developments, often including forward-looking statements and contact information—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a full financial report (10-K, IR) or a transcript (CT), and it focuses on scientific/clinical updates rather than management changes (MANG) or dividend notices (DIV), it fits best as an Earnings Release (ER) if it were tied to a reporting period, or a general Regulatory Filing (RNS). Given the context of a biotech company announcing trial updates and data presentations, this functions as a key corporate update, often released alongside or instead of a formal earnings report to disseminate material information. However, the content is purely scientific/clinical development news, not financial results highlights. The closest fit for a non-financial, material corporate announcement that isn't a specific report type is RNS, but ERs often include such operational updates. Since the document is a press release announcing scientific progress and an upcoming expert call, and it is not a full financial report, it is best classified as a general Regulatory Filing (RNS) or potentially an Earnings Release (ER) if this type of announcement is bundled there. Given the strong focus on clinical trial design and data presentation rather than financial metrics, RNS is the most appropriate fallback for a material, non-standard filing. Revisiting the definitions: ER is for 'initial announcement of quarterly/periodical financial results (key highlights only)'. This document does not contain financial highlights. Therefore, RNS (General regulatory announcements and fallback category) is the most suitable classification for this material, non-financial press release.
2019-06-12 French
Innate Pharma to present IPH4102 “TELLOMAK” clinical trial design and preclinical PTCL data at the 2019 ICML
Investor Presentation Classification · 1% confidence The document is explicitly titled "PRESS RELEASE" and announces that the company will present clinical trial design and preclinical data at an upcoming medical conference (2019 ICML). It details the trial design (TELLOMAK Phase II), expected timelines for updates, and includes background information on the drug (IPH4102) and the diseases it targets. This format—a formal announcement of scientific/clinical updates intended for investors and the public, often preceding a formal regulatory filing or earnings report—is characteristic of an Investor Presentation (IP) or a general press release detailing scientific progress. Since it is a detailed announcement focused on clinical data and strategy presentation rather than a formal regulatory filing (like 10-K or MRQ) or a transcript of a call, 'Investor Presentation' (IP) is the most fitting category, as these press releases often serve as the initial communication of such detailed scientific findings to the investment community, even if the full presentation material is separate. It is not an Earnings Release (ER) as it focuses on clinical trial updates, not financial results.
2019-06-12 English
Regulatory Filings 2019
Regulatory Filings
2019-06-08 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.